Sangamo Therapeutics (NASDAQ:SGMO) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) from a hold rating to a sell rating in a research report sent to investors on Friday.

A number of other equities analysts have also recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Barclays dropped their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $4.50.

Sangamo Therapeutics Trading Up 5.8%

Shares of SGMO traded up $0.03 during trading hours on Friday, reaching $0.50. 5,405,844 shares of the company's stock traded hands, compared to its average volume of 8,799,132. The stock has a market cap of $116.63 million, a PE ratio of -0.67 and a beta of 1.46. The firm's 50 day simple moving average is $0.63 and its 200-day simple moving average is $1.16. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The business had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. As a group, analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SGMO. E Fund Management Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at $25,000. JPMorgan Chase & Co. increased its position in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 25,000 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter worth about $28,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter worth about $30,000. 56.93% of the stock is owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.